Efficacy gap between phase II and subsequent phase III studies in oncology

AIMS: There is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all. This paper investigated the relation between phase II and III clinical trial efficacy in oncology....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Principais autores: Vreman, Rick A., Belitser, Svetlana V., Mota, Ana T.M., Hövels, Anke M., Goettsch, Wim G., Roes, Kit C.B., Leufkens, Hubert G.M., Mantel‐Teeuwisse, Aukje K.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318994/
https://ncbi.nlm.nih.gov/pubmed/32034790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados